The study, published in The Lancet, a team from the Moorfields Eye Hospital and University College London Institute of ...

Oncolytic virus therapy is emerging as a low-cost, targeted cancer treatment. With over 60 trials in China, scientists see ...

Amgen (AMGN) announced that the U.S. FDA has approved Uplizna as the first and only treatment for adults living with Immunoglobulin G4-related ...

Amgen said the Food and Drug Administration approved Uplizna for Immunoglobulin G4-related disease, the second approved indication. The biotechnology company said Thursday the FDA granted breakthrough ...

The FDA’s decision to grant Breakthrough Therapy Designation to UPLIZNA underscores the significant unmet medical need in ...

Brian Fiske, chief scientist at The Michael J. Fox Foundation for Parkinson’s Research, which funded some of Dr ...

The most exciting breakthrough is Adaptive Deep Brain Stimulation (aDBS), which reduces Parkinson’s symptoms by up to 50%. While earlier DBS devices gave the brain continuous electrical stimulation, ...

Center for Social Dynamics (CSD), leader in providing and innovating behavioral health services, today announced the ...

Imagine a super-charged immune cell that can launch a focused attack on stubborn solid tumors - a smart fighter that destroys ...

In an analysis of public health records in Wales has led Stanford researchers to believe that the shingles vaccine can reduce ...

RAD52 has already shown promise as a drug target. Inhibitors of the protein can selectively kill cancerous cells while ...